Utama › Kanser Metastatik › Utah
Kajian klinikal Kanser Metastatik di Utah
31 kajian untuk Kanser Metastatik sedang mencari peserta di lokasi di Utah.
Bandar di Utah
Teks kajian rasmi (Bahasa Inggeris)
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- University of Utah - Huntsman Cancer Institute, Salt Lake City
- START Mountain Region, West Valley City
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06465069A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- START Mountain Region, West Valley City
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06270706A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Intermountain Health, Salt Lake City
Mengambil pesertaFasa 1
Umur 19 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06586957A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
- ALX Center 4, West Valley City
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT07085091First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Sep 2026 · NCT05875168Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Mengambil pesertaFasa 2/3
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Sep 2026 · NCT06943755A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- START Mountain Region, LLC, West Valley City
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT07277413Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07222566A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Utah Cancer Specialists, Salt Lake City
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07174336A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Huntsman Cancer Institute, Salt Lake City
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07213804Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- University of Utah - Huntsman Cancer Institute, Salt Lake City
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Sep 2026 · NCT05267626CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
- Clinical Study Site, West Valley City
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 10 Sep 2026 · NCT07335497AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
- Avenzo Therapeutics Recruiting Site, West Valley City
Mengambil pesertaFasa 1/2
Umur 18 hingga 75 · Semua jantina · Dikemas kini 4 Sep 2026 · NCT07038343A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- South Texas Accelerated Research Therapeutics (START) Mountain Region, West Valley City
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Ogo 2026 · NCT07029399FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
- University of Utah, Salt Lake City
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 20 Ogo 2026 · NCT05614739A Study of MGC026 in Participants With Advanced Solid Tumors
- START Mountain Region, West Valley City
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 11 Ogo 2026 · NCT06242470A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors
- START Mountain Region, West Valley City
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 10 Ogo 2026 · NCT06880549Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
- Huntsman Cancer Institute/University of Utah, Salt Lake City
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 3 Ogo 2026 · NCT05687110A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
- Crinetics Study Site, Salt Lake City
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 31 Jul 2026 · NCT07129252A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Utah Cancer Specialists, Salt Lake City
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Jul 2026 · NCT04657068A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
- Huntsman Cancer Institute, University of Utah, Salt Lake City
- START Mountain Region, LLC., West Valley City
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Jul 2026 · NCT06657144A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Jun 2026 · NCT07458347A Study of LY4175408 in Participants With Advanced Cancer
- START Mountain Region, West Valley City
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Jun 2026 · NCT07046923BBO-11818 in Adult Subjects With KRAS Mutant Cancer
- Huntsman Cancer Institute, Salt Lake City
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Jun 2026 · NCT06917079Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Huntsman Cancer Institute, Salt Lake City
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Mei 2026 · NCT05379985A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- Huntsman Cancer Institute, Salt Lake City
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Apr 2026 · NCT07020221A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
- START Mountain Region, West Valley City
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Mac 2026 · NCT06244771Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
- START Mountain Region, West Valley City
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Feb 2026 · NCT07030257Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors
- Huntsman Cancer Institute at University of Utah, Salt Lake City
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 13 Feb 2026 · NCT06358677VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- Utah Cancer Specialists (site 203), Salt Lake City
Mengambil pesertaFasa 1/2
Umur 18 hingga 80 · Semua jantina · Dikemas kini 11 Dis 2025 · NCT03556228SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Salt Lake City
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 28 Okt 2025 · NCT03452774Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.